专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09175070B2 Neutralizing antibodies to HIV-1 and their use 有权
标题翻译：中和HIV-1的抗体及其用途
公开(公告)号：US09175070B2
公开(公告)日：2015-11-03
申请号：US13498125
申请日：2010-09-24
申请人： John R. Mascola , Richard T. Wyatt , Xueling Wu , Yuxing Li , Carl-Magnus Hogerkorp , Mario Roederer , Zhi-yong Yang , Gary J. Nabel , Peter D. Kwong , Tongqing Zhou , Mark Connors , William R. Schief
发明人： John R. Mascola , Richard T. Wyatt , Xueling Wu , Yuxing Li , Carl-Magnus Hogerkorp , Mario Roederer , Zhi-yong Yang , Gary J. Nabel , Peter D. Kwong , Tongqing Zhou , Mark Connors , William R. Schief
IPC分类号： C07K16/10 , A61K31/517 , A61K45/06
CPC分类号： C07K16/1063 , A61K39/42 , A61K45/06 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12N2740/10011 , C12N2740/16011 , C12N2740/16111
摘要： Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.
摘要翻译：公开了特异性结合HIV-1 gp120的CD4结合位点的单克隆中和抗体。还公开了特异性结合HIV-1 gp41的单克隆中和抗体。还公开了这些抗体的鉴定，以及这些抗体的用途。还提供了用于增强使用表位支架探针的任何抗体的结合和中和活性的方法。

2. 发明申请

US20120282264A1 NEUTRALIZING ANTIBODIES TO HIV-1 AND THEIR USE 有权
标题翻译：将抗体中和到HIV-1及其使用
公开(公告)号：US20120282264A1
公开(公告)日：2012-11-08
申请号：US13498125
申请日：2010-09-24
申请人： John R. Mascola , Richard Wyatt , Xueling Wu , Yuxing Li , Carl-Magnus Hogerkorp , Mario Roederer , Zhi-yong Yang , Gary Nabel , Peter Kwong , Tongqing Zhou , Mark Connors , Gilad Ofek , Lawrence Shapiro , Jiang Zhu , William R. Schief
发明人： John R. Mascola , Richard Wyatt , Xueling Wu , Yuxing Li , Carl-Magnus Hogerkorp , Mario Roederer , Zhi-yong Yang , Gary Nabel , Peter Kwong , Tongqing Zhou , Mark Connors , Gilad Ofek , Lawrence Shapiro , Jiang Zhu , William R. Schief
IPC分类号： C07K16/10 , A61K39/42 , C12N15/13 , C12N1/21 , C12N15/74 , G01N33/569 , A61P31/18 , G01N33/577 , C12N9/96 , C12N15/63
CPC分类号： C07K16/1063 , A61K39/42 , A61K45/06 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12N2740/10011 , C12N2740/16011 , C12N2740/16111
摘要： Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.
摘要翻译：公开了特异性结合HIV-1 gp120的CD4结合位点的单克隆中和抗体。还公开了特异性结合HIV-1 gp41的单克隆中和抗体。还公开了这些抗体的鉴定，以及这些抗体的用途。还提供了用于增强使用表位支架探针的任何抗体的结合和中和活性的方法。

3. 发明申请

US20110052631A1 INDUCTION OF PROLIFERATION, EFFECTOR MOLECULE EXPRESSION, AND CYTOLYTIC CAPACITY OF HIV-SPECIFIC CD8+ T CELLS 审中-公开
标题翻译：艾滋病毒特异性CD8 + T细胞的增殖，影响分子表达和CYTOLYIC能力的诱导
公开(公告)号：US20110052631A1
公开(公告)日：2011-03-03
申请号：US12934522
申请日：2009-03-25
申请人： Mark Connors , Stephen A. Migueles
发明人： Mark Connors , Stephen A. Migueles
IPC分类号： A61K39/21 , C12N5/078 , C12N5/0783 , A61P37/04 , A61P31/18
CPC分类号： A61K31/235 , A61K31/555 , A61K35/17 , A61K2035/124 , C12N5/0636 , C12N2500/14 , C12N2501/999 , A61K2300/00
摘要： Provided is a method of activating an immune cell of a subject with Human Immunodeficiency Virus (HIV), comprising contacting the immune cell with a phorbol ester and a calcium ionophore. Also provided is a composition comprising immune cells of a subject diagnosed with HIV, wherein the immune cells are activated by contact with a phorbol ester and a calcium ionophore. Methods of using the disclosed compositions are also disclosed.
摘要翻译：提供了一种用人免疫缺陷病毒（HIV）激活受试者的免疫细胞的方法，包括使免疫细胞与佛波酯和钙离子载体接触。还提供了包含被诊断为HIV的受试者的免疫细胞的组合物，其中所述免疫细胞通过与佛波酯和钙离子载体接触来活化。还公开了使用所公开的组合物的方法。

4. 发明申请

US20060086787A1 Systems and methods for facilitating purchases and tax recovery 审中-公开
标题翻译：促进采购和税收回收的制度和方法
公开(公告)号：US20060086787A1
公开(公告)日：2006-04-27
申请号：US11258089
申请日：2005-10-26
申请人： Robert Roy , Craig Watson , Paul Lersch , Mark Connors
发明人： Robert Roy , Craig Watson , Paul Lersch , Mark Connors
IPC分类号： G06K5/00 , G06Q20/00
CPC分类号： G06Q20/20 , G06Q20/14 , G06Q20/207 , G06Q20/387 , G07G1/14
摘要： A method includes storing information associated with at least one purchaser in a database. The information may include discount or rate information to be applied when calculating charges for purchases. The method also includes receiving, from a seller, payment card information associated with the sale of fuel to a first purchaser and determining whether the first purchaser is registered in the database. The method also includes calculating, when the first purchaser is registered in the database, a charge amount based on information stored in the database.
摘要翻译：一种方法包括将与至少一个购买者相关联的信息存储在数据库中。信息可能包括在计算购买费用时应用的折扣或费率信息。该方法还包括从卖方接收与第一购买者的燃料销售相关联的支付卡信息，并确定第一购买者是否在数据库中注册。该方法还包括基于存储在数据库中的信息计算第一购买者在数据库中注册的费用金额。

5. 发明授权

US08637036B2 Neutralizing antibodies to HIV-1 and their use 有权
标题翻译：中和HIV-1的抗体及其用途
公开(公告)号：US08637036B2
公开(公告)日：2014-01-28
申请号：US13429286
申请日：2012-03-23
申请人： John R. Mascola , Richard T. Wyatt , Xueling Wu , Yuxing Li , Carl-Magnus Hogerkorp , Mario Roederer , Zhi-yong Yang , Gary J. Nabel , Peter D. Kwong , Tongqing Zhou , Mark Connors , William R. Schief
发明人： John R. Mascola , Richard T. Wyatt , Xueling Wu , Yuxing Li , Carl-Magnus Hogerkorp , Mario Roederer , Zhi-yong Yang , Gary J. Nabel , Peter D. Kwong , Tongqing Zhou , Mark Connors , William R. Schief
IPC分类号： A61K39/42 , A61K39/21 , C12Q1/70
CPC分类号： C07K16/1063 , A61K39/42 , A61K45/06 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12N2740/10011 , C12N2740/16011 , C12N2740/16111
摘要： Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.
摘要翻译：公开了特异性结合HIV-1 gp120的CD4结合位点的单克隆中和抗体。还公开了特异性结合HIV-1 gp41的单克隆中和抗体。还公开了这些抗体的鉴定，以及这些抗体的用途。还提供了用于增强使用表位支架探针的任何抗体的结合和中和活性的方法。

6. 发明申请

US20120244166A1 NEUTRALIZING ANTIBODIES TO HIV-1 AND THEIR USE 审中-公开
标题翻译：将抗体中和到HIV-1及其使用
公开(公告)号：US20120244166A1
公开(公告)日：2012-09-27
申请号：US13429279
申请日：2012-03-23
申请人： John R. Mascola , Richard T. Wyatt , Xueling Wu , Yuxing Li , Carl-Magnus Hogerkorp , Mario Roederer , Zhi-yong Yang , Gary J. Nabel , Peter D. Kwong , Tongqing Zhou , Mark Connors , Gilad Ofek , Lawrence Shapiro , Jiang Zhu , William R. Schief
发明人： John R. Mascola , Richard T. Wyatt , Xueling Wu , Yuxing Li , Carl-Magnus Hogerkorp , Mario Roederer , Zhi-yong Yang , Gary J. Nabel , Peter D. Kwong , Tongqing Zhou , Mark Connors , Gilad Ofek , Lawrence Shapiro , Jiang Zhu , William R. Schief
IPC分类号： A61K39/395 , C12N15/63 , C12N1/21 , C12N1/19 , A61P31/18 , C12N15/74 , G01N21/64 , C07K16/10 , C12N15/13 , C12N9/96 , C12N5/10
CPC分类号： C07K16/1063 , A61K39/42 , A61K45/06 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12N2740/10011 , C12N2740/16011 , C12N2740/16111
摘要： Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and uses of these antibodies, are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.
摘要翻译：公开了特异性结合HIV-1 gp120的CD4结合位点的单克隆中和抗体。还公开了特异性结合HIV-1 gp41的单克隆中和抗体。还公开了这些抗体的鉴定以及这些抗体的用途。还提供了用于增强使用表位支架探针的任何抗体的结合和中和活性的方法。

7. 发明授权

US5922326A Attenuated respiratory syncytial virus vaccine compositions 失效
标题翻译：减毒呼吸道合胞病毒疫苗组合物
公开(公告)号：US5922326A
公开(公告)日：1999-07-13
申请号：US327263
申请日：1994-10-21
申请人： Brian R. Murphy , Robert M. Chanock , James E. Crowe, Jr. , Mark Connors
发明人： Brian R. Murphy , Robert M. Chanock , James E. Crowe, Jr. , Mark Connors
IPC分类号： C12N7/00 , A61K39/155 , A61K39/39 , A61P31/12 , A61P31/14 , C12N7/04 , C12N7/08
CPC分类号： C12N7/00 , A61K39/12 , A61K39/155 , A61K2039/5254 , A61K2039/543 , C12N2760/18534 , C12N2760/18561
摘要： The present invention provides vaccine compositions of attenuated respiratory syncytial virus (RSV). More particularly, the attenuated virus may be a derivative of RSV which has been incompletely attenuated by cold-passage or introduction of mutations which produce virus having a temperature sensitive (ts) or cold adapted (ca) phenotype. The invention also provides methods for stimulating the immune system of an individual to induce protection against respiratory syncytial virus by administration of attenuated RSV. The invention also provides pure cultures of attenuated RS virus, wherein the virus has been more completely attenuated by the further derivatization of previously identified incompletely attenuated ts or cp mutants.
摘要翻译：本发明提供减毒呼吸道合胞病毒（RSV）的疫苗组合物。更具体地，减毒病毒可以是RSV的衍生物，其通过冷通道或引入产生具有温度敏感（ts）或冷适应（ca）表型的病毒的突变而不完全减毒。本发明还提供了刺激个体的免疫系统以通过施用减毒RSV诱导针对呼吸道合胞病毒的保护的方法。本发明还提供了减毒RS病毒的纯培养物，其中通过进一步衍生以前鉴定的不完全衰减的ts或cp突变体，病毒已被更完全地减毒。

8. 发明授权

US5882651A Attenuated respiratory syncytial virus vaccine compositions 失效
公开(公告)号：US5882651A
公开(公告)日：1999-03-16
申请号：US453294
申请日：1995-05-30
申请人： Brian R. Murphy , Robert M. Chanock , James E. Crowe, Jr. , Mark Connors , Kuo-Hom Lee Hsu , Alan R. Davis , Michael D. Lubeck , Bernard H. Selling
发明人： Brian R. Murphy , Robert M. Chanock , James E. Crowe, Jr. , Mark Connors , Kuo-Hom Lee Hsu , Alan R. Davis , Michael D. Lubeck , Bernard H. Selling
IPC分类号： C12N7/00 , A61K39/155 , A61K39/39 , A61P31/12 , A61P31/14 , C12N7/04 , C12N7/06 , C12N7/08
CPC分类号： C12N7/00 , A61K39/12 , A61K39/155 , A61K2039/5254 , A61K2039/543 , C12N2760/18534 , C12N2760/18561
摘要： The present invention provides vaccine compositions of attenuated respiratory syncytial virus (RSV). More particularly, the attenuated virus may be a derivative of RSV which has been incompletely attenuated by cold-passage or introduction of mutations which produce virus having a temperature sensitive (ts) or cold adapted (ca) phenotype. The invention also provides methods for stimulating the immune system of an individual to induce protection against respiratory syncytial virus by administration of attenuated RSV. The invention also provides pure cultures of attenuated RS virus, wherein the virus has been more completely attenuated by the further derivatization of previously identified incompletely attenuated ts or cp mutants.

9. 发明申请

US20120237523A1 NEUTRALIZING ANTIBODIES TO HIV-1 AND THEIR USE 有权
公开(公告)号：US20120237523A1
公开(公告)日：2012-09-20
申请号：US13429286
申请日：2012-03-23
申请人： John R. Mascola , Richard T. Wyatt , Xueling Wu , Yuxing Li , Carl-Magnus Hogerkorp , Mario Roederer , Zhi-yong Yang , Gary J. Nabel , Peter D. Kwong , Tongqing Zhou , Mark Connors , Gilad Ofek , Lawrence Shapiro , Jiang Zhu , William R. Schief
发明人： John R. Mascola , Richard T. Wyatt , Xueling Wu , Yuxing Li , Carl-Magnus Hogerkorp , Mario Roederer , Zhi-yong Yang , Gary J. Nabel , Peter D. Kwong , Tongqing Zhou , Mark Connors , Gilad Ofek , Lawrence Shapiro , Jiang Zhu , William R. Schief
IPC分类号： A61K39/42 , C12N15/13 , A61P31/18 , G01N33/566 , G01N33/569 , C12N1/21 , C12N5/10 , C12N1/19 , C07K16/10 , C12N15/63
CPC分类号： C07K16/1063 , A61K39/42 , A61K45/06 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12N2740/10011 , C12N2740/16011 , C12N2740/16111
摘要： Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.

10. 发明授权

US06284254B1 Immunogenic compositions comprising cold-adapted attenuated respiratory syncytial virus mutants 失效
标题翻译：包含冷适应性减毒呼吸道合胞病毒突变体的免疫原性组合物
公开(公告)号：US06284254B1
公开(公告)日：2001-09-04
申请号：US08453304
申请日：1995-05-30
申请人： Brian R. Murphy , Robert M. Chanock , James E. Crowe, Jr. , Mark Connors , Kuo-Hom Lee Hsu , Alan R. Davis , Michael D. Lubeck , Bernard H. Selling
发明人： Brian R. Murphy , Robert M. Chanock , James E. Crowe, Jr. , Mark Connors , Kuo-Hom Lee Hsu , Alan R. Davis , Michael D. Lubeck , Bernard H. Selling
IPC分类号： A61K39155
CPC分类号： C12N7/00 , A61K39/12 , A61K39/155 , A61K2039/5254 , A61K2039/543 , C12N2760/18534 , C12N2760/18561
摘要： The respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in infants and children throughout the world. RSV is a major cause of pneumonia and bronchiolitis in infants under one year of age, and is a major cause of fatal respiratory tract disease in these infants. The treatment and prevention of RSV infection has been problematic. However, the present invention addresses some of these concerns by providing attenuated RSV strains that are suitable for inclusion in immunizing compositions. Specifically, the present invention is directed toward the introduction of growth restriction mutations into incompletely attenuated host range-restricted cold-passaged respiratory syncytial virus (cpRSV) strains by further passage of the strains at increasingly reduced temperatures to produce derivative strains which are more satisfactorily attenuated. These cold-adaptation (ca) approaches were used to introduce further attenuation in the parental RSV virus cpRSV-3131, which is incompletely attenuated in seronegative children. Mutants of the parental strain were obtained by selecting for large plaque production at reduced temperatures. An RSV cp-3131 derivative, designated D1, was isolated that produces large plaques at 25° C. Biologically cloned virus D1 produces distinctly and uniformly larger plaques at 25° C. as compared to the parental attenuated strain cpRSV-3131 or wild-type strain A2. Thus, D1 is an attenuated cold-adapted, but not temperature-sensitive, RSV mutant. The invention also provides methods for stimulating RSV-specific immune responses in an individual through the administration of said mutants.
摘要翻译：呼吸道合胞病毒（RSV）是全世界婴幼儿下呼吸道疾病的主要原因。 RSV是一岁以下婴儿肺炎和细支气管炎的主要原因，是这些婴儿致命性呼吸道疾病的主要原因。 RSV感染的治疗和预防是有问题的。然而，本发明通过提供适于包含在免疫组合物中的减毒RSV菌株来解决其中的一些问题。具体而言，本发明涉及通过在越来越多的降低的温度下进一步通过菌株，将生长限制性突变引入不完全减毒的宿主范围限制的冷传代呼吸道合胞病毒（cpRSV）菌株，以产生更令人满意地减毒的衍生菌株。这些冷适应（ca）方法用于在父母RSV病毒cpRSV-3131中引入进一步的衰减，其在血清阴性儿童中不完全减毒。通过在降低的温度下选择大的斑块产生来获得亲本菌株的突变体。分离出标记为D1的RSV cp-3131衍生物，其在25℃下产生大噬菌斑。与亲本减毒株cpRSV-3131或野生型相比，生物克隆病毒D1在25℃下产生明显均匀的大斑块菌株A2。因此，D1是减毒的冷适应但不是温度敏感的RSV突变体。本发明还提供了通过施用所述突变体来刺激个体中RSV特异性免疫应答的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式